ESTRO 2024 - Abstract Book

S1628

Clinical - Lung

ESTRO 2024

Keywords: cardiotoxicity, thoracic radiotherapy

References:

1- Slager, E., Wijsman, R., Van Melle, J.P., Hummel, Y.M., Bussink, J., Mohammed, N., Willems, T.P., Hoendermis, E.S., Langendijk, J.A., Muijs, C.T., & Van Luijk, P. (2020) Thoracic radiotherapy decreases right ventricle function: first results of the CLARIFY study. In ESTRO 2020 (pp. 255). https://user-swndwmf.cld.bz/8huStZo/255/

833

Digital Poster

Does NSCLC tumour volume impact the survival of curative-intent treatment? A real-word data analysis

Oluwasikemi Onamusi 1,2 , Azadeh Abravan 1,2 , Eliana Vasquez Osorio 1,2 , Hitesh Mistry 1 , Gareth Price 1,2 , Marcel Van Herk 1,2 , Corinne Faivre-Finn 1,2 1 The University of Manchester, Division of Cancer Sciences, Manchester, United Kingdom. 2 The Christie Hospital NHS Foundation Trust, Radiotherapy Related Research, Manchester, United Kingdom

Purpose/Objective:

Patients with stage III non-small cell lung cancer (NSCLC) and large volume tumours are generally less likely to be offered curative-intent radiotherapy (with or without chemotherapy) due to concerns that toxicity risks might outweigh potential benefits. This has led to low rates of patients with stage III NSCLC being treated with curative intent in the UK [1]. In this real-world study, we assessed how the survival of patients with NSCLC treated with different treatment regimens is related to tumour size.

Material/Methods:

We identified and retrieved the data of all stage III NSCLC patients treated at a single institution between 2013 and 2023. Clinical and tumour characteristics are collected directly from the electronic patient record using structured electronic forms. Radiotherapy dosimetric data was retrieved from Pinnacle. All data were accessed via the ukCAT Trusted Research Environment in accordance with research governance (UK ethical approval ref. NW/NW/0347). Patients treated with curative-intent radiotherapy were grouped into three categories: 1) concurrent chemo radiotherapy (cCRT), 2) sequential chemo-radiotherapy (sCRT), and 3) radiotherapy alone (RT). We further categorised the patients as having tumour volumes above or below the mean of the gross tumour volume (GTV) for the cohort (GTV mean ). Differential survival outcomes were compared using multivariable Cox regression, adjusting for age, gender, treatment, dose, GTV, performance status and comorbidities. Any potential interaction between the treatment received and GTV was also examined, using a likelihood ratio test (formal test).

Results: